Related Party Transactions - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		1 Months Ended	0 Months Ended		0 Months Ended		0 Months Ended	3 Months Ended		1 Months Ended	12 Months Ended	3 Months Ended		33 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Oct. 31, 2013 Fibrocell Science, Inc.	Dec. 17, 2013 Synthetic Biologics, Inc.	Mar. 31, 2014 Synthetic Biologics, Inc.	Sep. 30, 2013 Oragenics, Inc.	Mar. 31, 2014 Oragenics, Inc.	Nov. 20, 2013 Oragenics, Inc. Share Purchase Rights Plan	Mar. 31, 2014 Third Security	Mar. 31, 2013 Third Security	Jun. 06, 2011 Affiliates Of Third Security	Jun. 06, 2012 Affiliates Of Third Security	Mar. 31, 2014 Chief Executive Officer	Mar. 31, 2013 Chief Executive Officer	Oct. 31, 2013 Ziopharm Oncology, Inc.	Mar. 31, 2014 Ziopharm Oncology, Inc.
Related Party Transaction [Line Items]
Total amount of expenses reimbursed									$ 24	$ 81
Payment of license fee											9,000
Annual exclusivity fee												1,000
Milestone payments												54,000
Termination period												30 days
Compensation expense	470	388											470	388
Purchase of additional common stock																50,000
Shares of common stock purchased from collaborative partners															30,982
Purchase commitment																$ 19,018
Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase					19.99%		30.00%
Additional shares of collaborative partner to which the entity is entitled to purchase on the open market					10.00%
Shares of common stock purchased from collaborative partners			2,439,024	2,000,000		1,300,000		1,100,000
Price per share of common shares			$ 4.10	$ 1.00		$ 3.00		$ 2.50